A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function
(2023) In EMBO Molecular Medicine 15(2). p.1-21- Abstract
Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments. Here, we have generated antibodies derived from the memory B cells of an individual who had successfully cleared a group A streptococcal infection. The antibodies bind with high affinity in the central region of the surface-bound M protein. Such antibodies are typically non-opsonic. However, one antibody could effectively promote vital immune functions, including phagocytosis and in vivo protection. Remarkably, this antibody primarily interacts through a bivalent dual-Fab cis mode, where the Fabs bind to two distinct epitopes in the M protein. The dual-Fab cis-binding phenomenon is... (More)
Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments. Here, we have generated antibodies derived from the memory B cells of an individual who had successfully cleared a group A streptococcal infection. The antibodies bind with high affinity in the central region of the surface-bound M protein. Such antibodies are typically non-opsonic. However, one antibody could effectively promote vital immune functions, including phagocytosis and in vivo protection. Remarkably, this antibody primarily interacts through a bivalent dual-Fab cis mode, where the Fabs bind to two distinct epitopes in the M protein. The dual-Fab cis-binding phenomenon is conserved across different groups of M types. In contrast, other antibodies binding with normal single-Fab mode to the same region cannot bypass the M protein's virulent effects. A broadly binding, protective monoclonal antibody could be a candidate for anti-streptococcal therapy. Our findings highlight the concept of dual-Fab cis binding as a means to access conserved, and normally non-opsonic regions, regions for protective antibody targeting.
(Less)
- author
- organization
-
- epIgG (research group)
- Quantitative immunobiology (research group)
- Infection Medicine (BMC)
- BioMS (research group)
- Molecular Pathogenesis (research group)
- Immunomodulatory effects of platelets during inflammation and infection (research group)
- Infection Medicine Proteomics (research group)
- Autoimmunity and kidney diseases (research group)
- Nephrology
- SEBRA Sepsis and Bacterial Resistance Alliance (research group)
- Mass Spectrometry
- NanoLund: Centre for Nanoscience
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- in
- EMBO Molecular Medicine
- volume
- 15
- issue
- 2
- pages
- 1 - 21
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:36507602
- scopus:85143836581
- ISSN
- 1757-4684
- DOI
- 10.15252/emmm.202216208
- project
- Properties of Protective Antibody Responses against Bacterial Pathogens
- language
- English
- LU publication?
- yes
- additional info
- © 2022 The Authors. Published under the terms of the CC BY 4.0 license.
- id
- 19c5ce3d-8c88-431d-9380-05164456031b
- date added to LUP
- 2022-12-14 10:42:34
- date last changed
- 2024-09-29 20:47:51
@article{19c5ce3d-8c88-431d-9380-05164456031b, abstract = {{<p>Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments. Here, we have generated antibodies derived from the memory B cells of an individual who had successfully cleared a group A streptococcal infection. The antibodies bind with high affinity in the central region of the surface-bound M protein. Such antibodies are typically non-opsonic. However, one antibody could effectively promote vital immune functions, including phagocytosis and in vivo protection. Remarkably, this antibody primarily interacts through a bivalent dual-Fab cis mode, where the Fabs bind to two distinct epitopes in the M protein. The dual-Fab cis-binding phenomenon is conserved across different groups of M types. In contrast, other antibodies binding with normal single-Fab mode to the same region cannot bypass the M protein's virulent effects. A broadly binding, protective monoclonal antibody could be a candidate for anti-streptococcal therapy. Our findings highlight the concept of dual-Fab cis binding as a means to access conserved, and normally non-opsonic regions, regions for protective antibody targeting.</p>}}, author = {{Bahnan, Wael and Happonen, Lotta and Khakzad, Hamed and Kumra Ahnlide, Vibha and de Neergaard, Therese and Wrighton, Sebastian and André, Oscar and Bratanis, Eleni and Tang, Di and Hellmark, Thomas and Björck, Lars and Shannon, Oonagh and Malmström, Lars and Malmström, Johan and Nordenfelt, Pontus}}, issn = {{1757-4684}}, language = {{eng}}, number = {{2}}, pages = {{1--21}}, publisher = {{Wiley-Blackwell}}, series = {{EMBO Molecular Medicine}}, title = {{A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function}}, url = {{http://dx.doi.org/10.15252/emmm.202216208}}, doi = {{10.15252/emmm.202216208}}, volume = {{15}}, year = {{2023}}, }